Mutual Funds
Mutual Funds
Fund Profile
Scheme Profile
Daily NAV
Historical NAV
Category Returns
Dividend Details
Fund Ranking
MF Activities
All Holdings
What's In / What's Out
MF Trends
MF Tools
  Home   >   MUTUAL FUND  >  MUTUAL FUNDS  >  CATEGORY RETURNS
CATEGORY RETURNS      
AMC : Category : Scheme :
Nippon India Nifty Pharma ETF
TypeInvestment In% of NAVNo. of sharesValue (Rs cr)
Domestic EquitiesSun Pharmaceutical Industries Limited25.53361237230226.6977
Domestic EquitiesCipla Limited11.2712645572100.0701
Domestic EquitiesDivi's Laboratories Limited9.990514572088.6998
Domestic EquitiesDr. Reddy's Laboratories Limited9.334270000282.8732
Domestic EquitiesLupin Limited6.542327717658.0850
Domestic EquitiesTorrent Pharmaceuticals Limited4.490912002439.8720
Domestic EquitiesAurobindo Pharma Limited4.442932093239.4458
Domestic EquitiesMankind Pharma Limited3.598512959631.9493
Domestic EquitiesAlkem Laboratories Limited3.51346097231.1933
Domestic EquitiesLaurus Labs Limited3.054444909427.1185
Domestic EquitiesZydus Lifesciences Limited2.867628662925.4598
Domestic EquitiesGlenmark Pharmaceuticals Limited2.687717276923.8629
Domestic EquitiesIPCA Laboratories Limited2.516715946822.3447
Domestic EquitiesAbbott India Limited2.0196598017.9310
Domestic EquitiesBiocon Limited1.873151679416.6304
Domestic EquitiesJB Chemicals & Pharmaceuticals Limited1.49458229413.2691
Domestic EquitiesAjanta Pharma Limited1.47324833313.0794
Domestic EquitiesGland Pharma Limited1.43999131312.7838
Domestic EquitiesNatco Pharma Limited0.98421026918.7380
Domestic EquitiesGranules India Limited0.85371662887.5794
Total 99.9821 887.6832
Cash & Cash Equivalents and Net AssetsTriparty Repo0.0396 0.3514
Cash & Cash Equivalents and Net AssetsCash Margin - CCIL0.0002 0.0021
Cash & Cash Equivalents and Net AssetsNet Current Assets-0.0219 -0.1943
Total 0.0179 0.1592
 
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.